References
- Rupp A, Keith SJ. The costs of schizophrenia. Assessing the burden. Psychiatric Clinics of North America 1993; 16: 413–423. 2. Rice DP. The economic impact of schizophrenia. Journal of Clinical Psychiatry 1999; 60 (Suppl.1): 4–6.
- Knapp M. Costs of schizophrenia. British Journal of Psychiatry 1997; 171: 509–518.
- Guest JF, Cookson RF. Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 1999; 15: 597–610.
- Davies L, Drummond M. The economic burden of schizophrenia. Psychological Bulletin 1990; 14: 522–525.
- Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 2000; 321: 1371–1376.
- Speller JC, Barnes TR, Curson DA, Pantelis C, Alberts JL. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. British Journal of Psychiatry 1997; 171: 564–568.
- Coukell A, Spencer C, Benfield P. Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1996; 6: 237–256.
- Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. British Journal of Psychiatry 1997; 170: 18-22.
- Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. American Journal of Psychiatry 1999; 156: 610–616.
- Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. American Journal of Psychiatry 1995; 152: 130–134.
- Souêtre E, Martin P, Lecanu J et al. Evaluation medico-economique des la schizophrenie. L’Encephale 1992; 18: 253–269.
- Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Rein W. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Research 1999; 88: 107–117.
- Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y, and the Amisulpride Study Group. Amisulpride versus risperidone in chronic schizophrenia: results of a 6-month, double-blind study. Neuropsychopharmacology 2002; 27: 1071-1081.
- Netten A, Curtis L. Unit costs of Health and Social Care 2000. Canterbury: Personal Social Services Research Unit, University of Kent, 2000.
- Bow-Thomas CC, Velligan DI, Miller AL, Olsen J. Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization. Psychiatry Research 1999; 86: 131–142.
- Outcomes assessment of Solian in schizophrenia (OASIS): intermediate results of a French study. Presented at World Congress of Biological Psychiatry, Berlin: 2000.
- Almond S, O’Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000; 17: 383–389.
- Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost- effectiveness clinical decision analysis model for schizophrenia. American Journal of Managed Care 1998; 4: 345–355.
- Davies A, Langley PC, Keks NA, Catts SV, Lambert T, Schweitzer I. Risperidone versus haloperidol: II. Cost-effectiveness. Clinical Therapeutics 1998; 20: 196–213.
- Nightengale BS, Crumly JM, Liao J, Lawrence BJ, Jacobs EW. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone. Psychopharmacology Bulletin 1998; 34: 373–382.